financetom
Business
financetom
/
Business
/
Rivian Shares Surge As Q3 Loss Narrows, R2 Progress Continues
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Rivian Shares Surge As Q3 Loss Narrows, R2 Progress Continues
Nov 5, 2025 8:50 AM

Shares of Rivian Automotive Inc ( RIVN ) are trading higher Wednesday morning after the electric vehicle maker reported third-quarter financial results that beat analyst expectations. Here’s what investors need to know.

RIVN is charging ahead with explosive momentum. Find out why here.

What To Know: The EV company announced total revenue of $1.56 billion, a 78% increase year-over-year, surpassing the Street consensus estimate of $1.50 billion. Rivian also reported a consolidated gross profit of $24 million for the quarter. The company posted a loss of 65 cents per share, which was better than the analyst consensus estimate for a loss 72 cents per share.

In the third quarter, Rivian delivered 13,201 vehicles. For its full-year 2025 guidance, Rivian maintained its vehicle delivery forecast of 41,500 to 43,500 vehicles. The company also guided for a full-year adjusted EBITDA loss between $2.0 billion and $2.25 billion.

Key operational updates included confirmation that its next-generation R2 vehicle remains on track for deliveries in the first half of 2026. Rivian also announced it will host an “Autonomy & AI day” on Dec. 11.

Benzinga Edge Rankings: According to Benzinga Edge Rankings, RIVN stock has a Momentum score of 46.62 and a Growth score of 24.90.

RIVN Price Action: Rivian Automotive ( RIVN ) shares were up 13.84% at $14.23 at the time of publication on Wednesday, according to Benzinga Pro data.

Read Also: Quantum Stocks Fight Back: Slight Rebound On Advances And Funding

How To Buy RIVN Stock

By now you're likely curious about how to participate in the market for Rivian Automotive ( RIVN ) – be it to purchase shares, or even attempt to bet against the company.

Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy “fractional shares,” which allows you to own portions of stock without buying an entire share.

If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to “go short” a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.

Image: Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
JPMorgan's Net Interest Income Outlook Is 'Moderate Disappointment' Amid 'Solid' Q1 Results, HSBC Says
JPMorgan's Net Interest Income Outlook Is 'Moderate Disappointment' Amid 'Solid' Q1 Results, HSBC Says
Apr 12, 2024
12:02 PM EDT, 04/12/2024 (MT Newswires) -- JPMorgan Chase's ( JPM ) net interest income outlook this year probably was assessed as a moderate disappointment amid solid Q1 results on a decrease in loan losses, higher non-interest income and lower expenses, HSBC Global Research said Friday in a note. JPMorgan ( JPM ) kept its 2024 net interest income outlook...
Penny Stock PaxMedica's African Sleeping Sickness Candidate Moves Closer To FDA Marketing Application Submission, Stock Rallies
Penny Stock PaxMedica's African Sleeping Sickness Candidate Moves Closer To FDA Marketing Application Submission, Stock Rallies
Apr 12, 2024
Friday, PaxMedica Inc ( PXMD ) completed the execution of its three pivotal registration/validation batches of PAX-101, an IV formulation of suramin.  This achievement is an essential milestone in enabling a New Drug Application submission to the FDA, which is currently planned for Q4 2024, and the potential commercial availability in the U.S. of the first and only form of suramin for Stage...
Netflix Likely to See Higher Q1 Revenue as Paid Sharing Benefits Continue, Oppenheimer Says
Netflix Likely to See Higher Q1 Revenue as Paid Sharing Benefits Continue, Oppenheimer Says
Apr 12, 2024
12:05 PM EDT, 04/12/2024 (MT Newswires) -- Netflix ( NFLX ) is likely to report higher Q1 revenue April 18 as long-tail benefits of paid sharing become increasingly evident, Oppenheimer said in a note Thursday. Analysts, including Jason Helfstein, said that Netflix ( NFLX ) has captured about 20% of the 100 million disclosed opportunity for paid sharing, and could...
Citi poaches back banker who had quit to join JPM, sources say
Citi poaches back banker who had quit to join JPM, sources say
Apr 12, 2024
By Shankar Ramakrishnan April 12 (Reuters) - Citigroup ( C/PN ) has rehired an investment banker who had quit to work for JPMorgan Chase ( JPM ) even before he started work there, two sources with knowledge of the matter said on Friday. Arvind Vashistha was on gardening leave after leaving his job at Citi in early February to join...
Copyright 2023-2026 - www.financetom.com All Rights Reserved